DK0534445T3 - Fremgangsmåde til fremstilling af et lægemiddel til oral eller topisk administrering ved behandling af Leishmaniasis - Google Patents

Fremgangsmåde til fremstilling af et lægemiddel til oral eller topisk administrering ved behandling af Leishmaniasis

Info

Publication number
DK0534445T3
DK0534445T3 DK92116415T DK92116415T DK0534445T3 DK 0534445 T3 DK0534445 T3 DK 0534445T3 DK 92116415 T DK92116415 T DK 92116415T DK 92116415 T DK92116415 T DK 92116415T DK 0534445 T3 DK0534445 T3 DK 0534445T3
Authority
DK
Denmark
Prior art keywords
group
medicament
oral
treatment
topical administration
Prior art date
Application number
DK92116415T
Other languages
Danish (da)
English (en)
Inventor
Hansjoerg Prof Dr Eibl
Clemens Dr Unger
Juergen Prof Dr Engel
Original Assignee
Max Planck Gesellschaft
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft, Asta Medica Ag filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of DK0534445T3 publication Critical patent/DK0534445T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
DK92116415T 1991-09-27 1992-09-24 Fremgangsmåde til fremstilling af et lægemiddel til oral eller topisk administrering ved behandling af Leishmaniasis DK0534445T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4132344A DE4132344A1 (de) 1991-09-27 1991-09-27 Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis

Publications (1)

Publication Number Publication Date
DK0534445T3 true DK0534445T3 (da) 1999-10-18

Family

ID=6441697

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92116415T DK0534445T3 (da) 1991-09-27 1992-09-24 Fremgangsmåde til fremstilling af et lægemiddel til oral eller topisk administrering ved behandling af Leishmaniasis

Country Status (13)

Country Link
US (1) US5980915A (ko)
EP (1) EP0534445B1 (ko)
JP (2) JP3587862B2 (ko)
KR (2) KR100270255B1 (ko)
AT (1) ATE177950T1 (ko)
BR (1) BR9203768A (ko)
DE (2) DE4132344A1 (ko)
DK (1) DK0534445T3 (ko)
ES (1) ES2132101T3 (ko)
GR (1) GR3030016T3 (ko)
HK (1) HK1004472A1 (ko)
MX (1) MX9205466A (ko)
SG (1) SG49692A1 (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254879B1 (en) * 1991-09-27 2001-07-03 Max-Planck-Gessellschaft zun Förderung der Wissenschaften e.V. Methods of treating protozoal diseases
US5681829A (en) * 1992-10-08 1997-10-28 Shaman Pharmaceuticals, Inc. Class of phosphocholine derivatives having antifungal activity
DE4305553A1 (de) * 1992-12-18 1994-06-23 Rhone Poulenc Rorer Gmbh Pharmazeutisches und/oder kosmetisches Mittel
SK284839B6 (sk) * 1998-01-22 2005-12-01 Zentaris Gmbh Použitie miltefozínu na výrobu lieku a farmaceutická kombinácia na liečenie leishmanózy
DE19835611A1 (de) * 1998-08-06 2000-02-10 Max Planck Gesellschaft Neuartige Phospholipide mit synthetischen, ungesättigten Alkyl- und Acylketten
DE10015814A1 (de) * 2000-03-30 2001-10-11 Max Planck Gesellschaft Arzneimittel zur Stimulierung der Leukopoese, zur Behandlung von Tumor- und Protozoenerkrankungen und Verfahren zu seiner Herstellung
DE10025124B4 (de) * 2000-05-20 2015-07-16 Beiersdorf Ag Kombinationen von Glycerinmonoalkylethern und Aryl-substituierten Alkoholen
DE10025122A1 (de) * 2000-05-20 2001-11-22 Beiersdorf Ag Kombinationen von Clycerinmonoalkylethern und Fettsäreglyceriden
BG64968B1 (bg) * 2000-08-07 2006-11-30 Asta Medica Aktiengesellschaft Твърди фармацевтични състави, съдържащи милтефозин за орално приложение при лечението на leishmaniasis
US7887817B2 (en) 2002-01-25 2011-02-15 Aeterna Zentaris Gmbh Process for preventing protozoal diseases
DE10203195A1 (de) * 2002-01-25 2003-08-07 Zentaris Ag Verwendung von Alkylphosphocholinen in der Präventivbehandlung von Protozoenerkrankungen
AU2003285071A1 (en) * 2002-10-30 2004-06-07 Nikolaos Avlonitis Antiprotozoal ring-substituted phospholipids
EP1800684A1 (en) * 2005-12-20 2007-06-27 Zentaris GmbH Novel alkyl phospholipid derivatives and uses thereof
CN101340918B (zh) * 2005-12-19 2012-10-03 阿特纳赞塔里斯有限公司 具有降低细胞毒性的新烷基磷脂衍生物及其用途
AR058397A1 (es) * 2005-12-19 2008-01-30 Zentaris Gmbh Derivados de alquilfosfolipidos con citotoxicidad reducida y usos de los mismos
DE102007014375A1 (de) 2007-03-26 2008-10-02 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Oleylphosphocholin
EA021785B1 (ru) 2009-07-09 2015-08-31 Пауль Менг Жидкая фармацевтическая форма алкилфосфохолина и способ её приготовления
US9358244B2 (en) 2010-11-22 2016-06-07 Oblita Therapeutics Bvba Solid dosage forms of oleyl phosphocholine
MX2020010741A (es) * 2018-04-10 2020-11-09 Cellectar Biosciences Inc Conjugados de fosfolipido-flavaglina y metodos para usar los mismos para la terapia dirigida al cancer.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5984824A (ja) * 1982-11-08 1984-05-16 Takeda Chem Ind Ltd 抗腫瘍剤
IE59777B1 (en) * 1985-12-04 1994-04-06 Max Planck Gesellschaft Medicaments
US5087721A (en) * 1987-10-23 1992-02-11 The University Of Michigan Radioiodinated phosphate esters
WO1989010370A1 (en) * 1988-04-19 1989-11-02 Cl-Pharma Aktiengesellschaft New alkylphosphono- and phosphoserines, method for preparing them, and pharmaceutical substances containing them

Also Published As

Publication number Publication date
KR100283783B1 (ko) 2001-02-15
US5980915A (en) 1999-11-09
KR100270255B1 (ko) 2002-09-04
EP0534445A1 (de) 1993-03-31
DE59209663D1 (de) 1999-04-29
HK1004472A1 (en) 1998-11-27
BR9203768A (pt) 1993-04-20
GR3030016T3 (en) 1999-07-30
ATE177950T1 (de) 1999-04-15
JPH06263643A (ja) 1994-09-20
MX9205466A (es) 1993-05-01
KR930005622A (ko) 1993-04-20
DE4132344A1 (de) 1993-04-01
ES2132101T3 (es) 1999-08-16
SG49692A1 (en) 1998-06-15
JP2004315540A (ja) 2004-11-11
JP3587862B2 (ja) 2004-11-10
EP0534445B1 (de) 1999-03-24

Similar Documents

Publication Publication Date Title
DK0534445T3 (da) Fremgangsmåde til fremstilling af et lægemiddel til oral eller topisk administrering ved behandling af Leishmaniasis
DE69201948D1 (de) Verwendung von 1,3-oxathiolanalogen von nukleosiden zur herstellung eines arzneimittels zur behandlung von hepatitis-b.
CA2039197A1 (en) Pharmaceutic Formulation for the Treatment of Alcoholism
HU9301579D0 (en) Compounds having medical effect
FR2361901A1 (fr) Derives de substitution de nucleotides et medicament contenant ces substances
NO158678C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive vicinale dihydroksyalkyl-xantiner.
ES2087625T3 (es) Derivados de ciclohexano sustituidos, procedimiento para su preparacion y el empleo de los compuestos para el tratamiento de enfermedades.
RU94045278A (ru) Применение 2-фенил-3-ароилбензтиофенов для ингибирования вазомоторных симптомов и сопутствующих психологических нарушений, ассоциированных с постклимактерическим синдромом
CA2003289A1 (en) Use of trifluoromethylphenyl-tetrahydropyridines for the preparation of pharmaceutical compositions useful for the treatment of anxiety and anxio-depressive disorders
FI922930A0 (fi) Foerfarande foer framstaellning av diacetylrhein.
HU9200335D0 (en) Medical products with human interleukin-2 content
HUT49283A (en) Process for production of medical compositions applicable for treatment of peptical ulcer
DE3870167D1 (de) N-(vinblastinoyl-23)-derivate von 1-aminomethylposphonsaeure, verfahren zu ihrer herstellung und sie enthaltende arzneimittel.
IT1256178B (it) Composti ad attivita' terapeutica utili per il trattamento di malattieconnesse ad una carenza di glutatione, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
HUT48265A (en) Process for producing phosphorous-containing 2-isoxazolines and isoxazoles and pharmaceutical compositions containing them or theyr salts as active components
EA200001028A1 (ru) Производные 2"-деоксигигромицина
EP0317933A3 (en) Treatment of fibromyalgia
EP0551844A3 (ko)
DE69818060D1 (de) Polyhydroxyalkylpyrazine derivate, deren herstellung,diese enthaltende arzneimitteln
IL57513A0 (en) 1,3-diaminopropan-2-ol derivatives,their preparation and pharmaceutical compositions containing them
FR2481697B1 (ko)
IT1248558B (it) Derivati della fisovenina utili per il trattamento delle malattie associate a disordini colinergici, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
GB2316406A (en) Free radical scavenger molecules
DE3777270D1 (de) Verwendung von l-carnitin zur herstellung eines arzneimittels zur behandlung von toxischen effekten, induziert durch die inhalation von halotan und anderen halogen enthaltenden allgemeinen anaesthetika.
FR2376151A1 (fr) Derives de pyrimidoquinoxaline, procede pour leur preparation et medicament contre l'asthme allergique contenant ces derives